Could Nektar Product NKTR-214 Become a Blockbuster?

Nektar Therapeutics NKTR-214: A Blockbuster?
Nektar Therapeutics (NKTR) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin (bempeg) succeeded in revealing the details of the drug’s actions that led to its successful outcome when used in monotherapy or in combination therapy in treating of various cancers.    

The product, which is a CD122-preferential interleukin-2 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.